In contrast, recent studies showed that Rab25 expression is decreased in human colon cancers and triple-negative (negative for estrogen receptor (ER), progesterone receptor (PR), and Her2/Neu) breast cancers, and Rab25 functions as a tumor suppressor in these cancers [41–43]. Here, RAB25 is linked to neoplasm.